All In Biotech

Drug Trial Radar · NCT01706198

An Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Asthma

A 12-month, Open Label, Randomised, Effectiveness Study to Evaluate Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) Inhalation Powder Delivered Once Daily Via a Novel Dry Powder Inhaler Compared With Usual Maintenance Therapy in Subjects With Asthma

Last checked: Nov 19, 2026Latest source record: Jan 24, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 4,233 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

4,233

Actual

Start

Nov 1, 2012

Primary completion

Dec 1, 2016

Study completion Dec 16, 2016

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Oct 15, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to compare the effectiveness and safety of Fluticasone Furoate/Vilanterol Inhalation Powder (100mcg Fluticasone Furoate ((FF), GW685698)/25mcg Vilanterol ((VI), GW642444) or 200mcg Fluticasone Furoate ((FF), GW685698)/25mcg Vilanterol ((VI), GW642444) ) delivered once daily via a Novel Dry Powder Inhaler (NDPI) compared with the existing asthma maintenance therapy over twelve months in subjects diagnosed with asthma. This is a Phase III multi-centre, randomised open label study. Subjects who meet the eligibility criteria are randomised and will enter a 12 month treatment period.

Conditions

  • Asthma

Interventions

  • fluticasone furoate + vilanterolDrug

    once daily via a Novel Dry Powder Inhaler

  • inhaled corticosteroid with or without a long acting beta2-agonistDrug

    ICS alone or in combination with a long acting bronchodilator

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Who Have Either an Asthma Control Test (ACT) Total Score of >=20 or an Increase From Baseline of >=3 in ACT Total Score at Week 24.Time frame: Baseline (Day 0) and Week 24

Locations

180 sites in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Cadishead, Manchester, United Kingdom

  • GSK Investigational Site

    Cheadle, United Kingdom

  • GSK Investigational Site

    Eccles, United Kingdom

  • GSK Investigational Site

    Eccles, Manchester, United Kingdom

  • GSK Investigational Site

    Eccles, Manchester, United Kingdom

  • GSK Investigational Site

    Eccles, Manchester, United Kingdom

  • GSK Investigational Site

    Eccles, Manchester, United Kingdom

  • GSK Investigational Site

    Eccles, Manchester, United Kingdom

  • GSK Investigational Site

    Eccles, Manchester, United Kingdom

  • GSK Investigational Site

    Eccles, Manchester, United Kingdom

  • GSK Investigational Site

    Eccles, Manchester, United Kingdom

  • GSK Investigational Site

    Eccles, Manchester, United Kingdom

  • GSK Investigational Site

    Eccles, Manchester, United Kingdom

  • GSK Investigational Site

    Eccles, Manchester, United Kingdom

  • GSK Investigational Site

    Eccles, Manchester, United Kingdom

  • GSK Investigational Site

    Ellenbrook, Manchester, United Kingdom

  • GSK Investigational Site

    Irlam, Manchester, United Kingdom

  • GSK Investigational Site

    Irlam, Manchester, United Kingdom

  • GSK Investigational Site

    Irlam, Manchester, United Kingdom

  • GSK Investigational Site

    Irlam, Manchester, United Kingdom

  • GSK Investigational Site

    Irlam, Manchester, United Kingdom

  • GSK Investigational Site

    Irlam, Salford, United Kingdom

  • GSK Investigational Site

    Little Hulton, Manchester, United Kingdom

  • GSK Investigational Site

    Little Hulton, Manchester, United Kingdom

  • GSK Investigational Site

    Little Hulton, Manchester, United Kingdom

  • GSK Investigational Site

    Little Hulton, Manchester, United Kingdom

  • GSK Investigational Site

    Little Hulton, Manchester, United Kingdom

  • GSK Investigational Site

    Little Hulton, Manchester, United Kingdom

  • GSK Investigational Site

    Manchester, United Kingdom

  • GSK Investigational Site

    Manchester, United Kingdom

  • GSK Investigational Site

    Manchester, United Kingdom

  • GSK Investigational Site

    Manchester, United Kingdom

  • GSK Investigational Site

    Manchester, United Kingdom

  • GSK Investigational Site

    Manchester, United Kingdom

  • GSK Investigational Site

    Manchester, United Kingdom

  • GSK Investigational Site

    Manchester, United Kingdom

  • GSK Investigational Site

    Manchester, United Kingdom

  • GSK Investigational Site

    Manchester, United Kingdom

  • GSK Investigational Site

    Manchester, United Kingdom

  • GSK Investigational Site

    Manchester, United Kingdom

Showing 40 of 180 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.